Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1873325 | 0.92 | S1PR1 (0.75) | S1PR1S1PR3 | |
| SCHEMBL677240 | 0.87 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL1871096 | 0.84 | S1PR1 (0.71) | S1PR1S1PR3 | |
| SCHEMBL1879240 | 0.82 | S1PR1 (0.68) | S1PR1S1PR3 | |
| SCHEMBL675979 | 0.81 | S1PR1 (0.85) | S1PR1S1PR3 | |
| SCHEMBL1875735 | 0.80 | S1PR1 (0.86) | S1PR1S1PR3 | |
| SCHEMBL16290130 | 0.79 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL675977 | 0.79 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL677093 | 0.79 | S1PR1 (1.00) | S1PR1S1PR3 | |
| Hydrochloric Acid SCHEMBL948459 | 0.78 | S1PR1 (1.00) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371811-A2 | Azetidinecarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-05 | — | — | EP | claimed |
| EP-2592066-B1 | Aminocarboxylic acid derivative and medical use thereof | ONO PHARMACEUTICAL CO (JP) | 2014-12-03 | — | — | EP | disclosed |
| US-20140023636-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-23 | — | — | US | disclosed |
| US-8575134-B2 | Aminocarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-2592066-A1 | Aminocarboxylic acid derivative and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-15 | — | — | EP | disclosed |
| EP-2371811-A2 | Azetidinecarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-05 | — | — | EP | disclosed |
| US-20110105432-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-7906549-B2 | Aminocarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090275554-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1826197-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105432-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | EDNRA, EDNRB, S1PR1 | S1PR1 3/4885S1PR3 15/4885 |
| US-20140023636-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | EDNRA, EDNRB, S1PR1 | S1PR1 3/4885S1PR3 15/4885 |
| US-20090275554-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | EDNRA, EDNRB, S1PR1 | S1PR1 3/4885S1PR3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.